265
Volume 5, Issue 10: Special Issue
(EJAR)
ISSN: 2181-2020
MPHAPP
THE 6TH INTERNATIONAL SCIENTIFIC AND PRACTICAL
CONFERENCE
“
MODERN PHARMACEUTICS: ACTUAL
PROBLEMS AND PROSPECTS
”
TASHKENT, OCTOBER 17, 2025
in-academy.uz
APPLICATION OF THE IMMOBILISATION METHOD TO INCREASE THE
STABILITY OF ENZYMES
Tillaeva G.U.
Abduvositova N.P.
Tillaeva U.M.
Rakhmanova Z.A.
Tashkent Pharmaceutical Institute, Tashkent city, Republic of Uzbekistan
e-mail: gulnoratillaeva@mail.ru, rzarina12345@mail.com
https://doi.org/10.5281/zenodo.17334104
Relevance:
It should be noted that enzymes have reciprocal and opposite processes, which
disrupts the stability of substances in combination with the second component. There are several ways
to avoid this: protecting active substances from acidic environments; prolonging the release of the
active destructive substance; and creating a multi-layered dosage form with programmable release
profiles for individual dosage selection. The combination of ibuprofen with serratiopeptidase, an
enzyme with anti-inflammatory and fibrinolytic effects, can reduce side effects. However, the low
stability of serratiopeptidase in the gastric environment requires the development of innovative
approaches.
In order to justify our selection, we conduct research with model drug mixtures of various
combinations and different coating (immobilisation) methods to create a stable drug mixture with
subsequent transfer of the composition into a rational dosage form.
Aim of the study:
To justify and conduct preliminary experimental research on a combined
drug based on serratiopeptidase and ibuprofen using immobilisation technologies aimed at increasing
the stability and bioavailability of the active substances.
Materials and methods:
Three delivery forms were used as research objects: MKTS (calcium
alginate matrix), MKTS Paxta (with stabiliser added), and Entrotsel (purified complex). The stability
and kinetics of active substance release were analysed using high-performance liquid chromatography
(HPLC) with the Farm HPLC system (DDD: 227, 223, 232 nm; FLD: Ex = 230 nm, Em = 460 nm).
The theoretical part of the study included an analysis of the prospects for using chitosan as a carrier,
taking into account its physicochemical and pharmaco-technological properties.
Results:
To create a stable medicinal model mixture, studies were conducted to justify the
selection of various combinations and different coating (immobilisation) methods. To develop a
method for quantifying the active ingredients – serratiopeptidase and ibuprofen – in the mixture
before and after coating (encapsulation) of the enzyme, high-performance liquid chromatography
(HPLC) with a spectrophotometric detector. According to HPLC data, it was found that MKTS Paxta
(locally produced) and Entrotsel (with added stabilisers) provide a more stable release of
serratiopeptidase and ibuprofen compared to the basic calcium alginate form. In particular, there is a
delayed and controlled release of active substances, which indicates the potential effectiveness of
these delivery systems. Theoretical analysis confirms that chitosan complexes have a number of
advantages, including resistance to acidic environments, mucoadhesiveness, and the ability to
increase bioavailability.
Conclusion:
Preliminary experimental data combined with theoretical analysis confirm the
promise of developing a combined drug based on serratiopeptidase and ibuprofen using innovative
delivery matrices. The most optimal forms appear to be MKTS Paxta with the addition of stabilisers
266
Volume 5, Issue 10: Special Issue
(EJAR)
ISSN: 2181-2020
MPHAPP
THE 6TH INTERNATIONAL SCIENTIFIC AND PRACTICAL
CONFERENCE
“
MODERN PHARMACEUTICS: ACTUAL
PROBLEMS AND PROSPECTS
”
TASHKENT, OCTOBER 17, 2025
in-academy.uz
or based on chitosan. The results open up opportunities for further research and development of an
effective prolonged-release dosage form.
